Cataloguing genomic abnormalities in pancreatic cancer
The goal of the APGI is to comprehensively catalogue the genomic and epigenomic abnormalities in pancreatic cancer. This will provide unprecedented new insights into the molecular biology of pancreatic cancer, and help promote research in developing new cancer treatments which are tailored towards individual patients. This will be Australia's contribution towards the world-wide efforts of the International Cancer Genome Consortium in compiling the genomic abnormalities of major human cancers and usher in the new era of personalised medicine.
State of the art sequencing technologies require high quality well annotated biospecimens
In order to achieve this, we are prospectively collecting and tissue banking high quality blood and tissue samples from consenting pancreatic cancer patients across Australia complete with deidentified clinical, pathological, treatment and follow-up outcome information. These specimens will then be globally sequenced using deep sequencing technologies, and the results analysed to discover potential driver and passenger mutations in pancreatic cancer. The flowchart below illustrates the key components which make up the APGI. If you are a patient and would like to participate, please contact us for more information.
- The International Cancer Genome Consortium (ICGC)
- Institute of Molecular Bioscience, Queensland Centre for Medical Genomics
- NHMRC and ICGC collaboration targets pancreatic cancer
- ICGC goals, structure, policies & guidelines can be found here